New pill shows promise against tough breast cancer

NCT ID NCT03624543

Ongoing Disease control Sponsor: Canadian Cancer Trials Group Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests an experimental drug called CFI-400945 in 51 people with advanced or metastatic breast cancer that has already been treated with chemotherapy. The goal is to see if the drug can shrink tumors or slow the disease. Participants take the drug in 28-day cycles, and researchers monitor tumor response and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CFI-400945 (an experimental oral drug)
What this could lead to: If it works, this could offer a new treatment option to slow or shrink advanced breast cancer that has not responded to standard chemotherapy.
What could go wrong: This is an early Phase 2 trial with only 51 participants, so results may not apply to all patients. The drug may cause side effects or fail to control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Allan Blair Cancer Centre

Regina, Saskatchewan, S4T 7T1, Canada
Juravinski Cancer Centre at Hamilton Health Sciences

Hamilton, Ontario, L8V 5C2, Canada
London Regional Cancer Program

London, Ontario, N6A 5W9, Canada
Odette Cancer Centre

Toronto, Ontario, M4N 3M5, Canada
Ottawa Hospital Research Institute

Ottawa, Ontario, K1H 8L6, Canada
University Health Network

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.